This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Antiviral therapy in patients with concomitant chronic hepatitis B and autoimmune diseases
Xiu-Cheng Pan, Jin-Song Ren
Xiu-Cheng Pan, Jin-Song Ren, Department of Infectious Diseases, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, Jiangsu Province, China
Correspondence to: Associated Professor Xiu-Cheng Pan, Department of Infectious Diseases, Affiliated Hospital of Xuzhou Medical College, 99 West Huaihai Road, Xuzhou, Jiangsu Province, China. xzpxc68@126.com
Received: January 17, 2011 Revised: May 15, 2011 Accepted: May 24, 2011 Published online: May 28, 2011
Chronic hepatitis B with concomitant autoimmune diseases is clinically common, and most of these patients need antiviral treatment. Each type of anti-HBV agent, such as nucleos(t)ide analogues and interferon-α, has its own unique advantages and disadvantages. Before selecting optimal antiviral therapy, we should evaluate these patients adequately to avoid iatrogenic injuries. For example, which autoimmune disease is the patients suffering from? How serious is the disease?
Citation: Pan XC, Ren JS. Antiviral therapy in patients with concomitant chronic hepatitis B and autoimmune diseases. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1629-1633
Stojkov D, Lavrnja I, Pekovic S, Dacic S, Bjelobaba I, Mostarica-Stojkovic M, Stosic-Grujicic S, Jovanovic S, Nedeljkovic N, Rakic L. Therapeutic effects of combined treatment with ribavirin and tiazofurin on experimental autoimmune encephalomyelitis development: clinical and histopathological evaluation.J Neurol Sci. 2008;267:76-85.
[PubMed] [DOI]
You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, Tang BZ, Huang ML, Ma YL, Chongsuvivatwong V. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.World J Gastroenterol. 2006;12:6715-6721.
[PubMed] [DOI]
Chien RN, Lin CY, Yeh CT, Liaw YF. Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C.J Viral Hepat. 2006;13:845-850.
[PubMed] [DOI]
Pierluigi B, D'Angelo C, Fallarino F, Moretti S, Zelante T, Bozza S, De Luca A, Bistoni F, Garaci E, Romani L. Thymosin alpha1: the regulator of regulators.Ann N Y Acad Sci. 2010;1194:1-5.
[PubMed] [DOI]
Chun S, Zucker SD. Combination therapy for chronic hepatitis B: a one-two knockout punch, or a swing and a miss.Gastroenterology. 2006;130:613-664; discussion 613-664.
[PubMed] [DOI]
Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, Salmeron J. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy.Arch Intern Med. 1998;158:1445-1448.
[PubMed] [DOI]
Kansu A, Kuloğlu Z, Demirçeken F, Girgin N. Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha.Turk J Gastroenterol. 2004;15:213-218.
[PubMed] [DOI]
Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno E, Meroni PL, Colombo M, Beck-Peccoz P. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a.Eur J Endocrinol. 1995;132:587-593.
[PubMed] [DOI]
Lv YY, Shi BY, Guo H. Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B.World J Gastroenterol. 2008;14:4713-4715.
[PubMed] [DOI]
Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C.Gastroenterology. 2006;130:225-230.
[PubMed] [DOI]
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update.Hepatology. 2009;49:1335-1374.
[PubMed] [DOI]
Panetta JD, Gilani N. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection.Aliment Pharmacol Ther. 2009;30:597-602.
[PubMed] [DOI]
Lee YN, Jeong SW, Lim JH, Ryu YS, Jeon SR, Kim SK, Jang JY, Kim YS, Kim BS, Roh MO. [Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C].Korean J Hepatol. 2010;16:187-191.
[PubMed] [DOI]
Cianciara J, Laskus T. Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B.Dig Dis Sci. 1995;40:1842-1844.
[PubMed] [DOI]
Mason AL, Farr GH, Xu L, Hubscher SG, Neuberger JM. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis.Am J Gastroenterol. 2004;99:2348-2355.
[PubMed] [DOI]
Lisker-Melman M, Webb D, Di Bisceglie AM, Kassianides C, Martin P, Rustgi V, Waggoner JG, Park Y, Hoofnagle JH. Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon.Ann Intern Med. 1989;111:479-483.
[PubMed] [DOI]
Szczepańska M, Tobis A, Schneiberg B, Szprynger K, Kobos E, Morawiec-Knysak A. [Treatment of chronic hepatitis with interferon in children with kidney diseases].Pol Merkur Lekarski. 2005;18:22-28.
[PubMed] [DOI]